Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARE: Darolutamide + Radium-223 in mCSPC
NCT05771896Phase 3Withdrawn
- Sponsor
- GenesisCare
- Start
- Sep 2023
- Primary completion
- Dec 2028
- Modality
- Radiopharmaceutical
01
Overview
A Phase 3 trial of radium-223 dichloride in prostate cancer (PCa), sponsored by GenesisCare. Planned start Sep 2023; status: withdrawn.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05771896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05771896.